CTI BioPharma Corp. Company Profile (NASDAQ:CTIC)

About CTI BioPharma Corp.

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL). It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. Its earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia (AML). It also evaluates its pipeline candidate paclitaxel poliglumex (Opaxio), which targets solid tumors. It is evaluating Opaxio through cooperative group sponsored trials and investigator-sponsored trials (ISTs), such as the ongoing maintenance therapy trial in patients with ovarian cancer.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: CTIC
CUSIP:

Key Metrics:

Previous Close: $0.39
50 Day Moving Average: $0.369
200 Day Moving Average: $0.428
52-Week Range: $279,604,000.00 - $0.25
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -1.67
P/E Growth: 0.000
Market Cap: $107.65M
Outstanding Shares: 279,604,000
Beta: 1.13

Profitability:

Net Margins: -133.07%
Return on Equity: -268.19%
Return on Assets: -69.71%

Debt:

Debt-to-Equity Ratio: 0.42%
Current Ratio: 2.18%
Quick Ratio: 2.12%

Additional Links:

Companies Related to CTI BioPharma Corp.:

Consensus Ratings for CTI BioPharma Corp. (NASDAQ:CTIC) (?)

Ratings Breakdown:	1 Sell Rating, 2 Hold Ratings
Consensus Rating:	Hold (Score: 1.67)
Consensus Price Target:	$0.91 (137.23% upside)

Analysts' Ratings History for CTI BioPharma Corp. (NASDAQ:CTIC)

Show:

Date	Firm	Action	Rating	Price Target
8/29/2016	Piper Jaffray Cos.	Reiterated Rating	Neutral	$0.75
2/10/2016	Ladenburg Thalmann	Downgrade	Buy -> Neutral
2/10/2016	WallachBeth Capital	Downgrade	Hold -> Sell
2/8/2016	S&P Equity Research	Lower Price Target		$0.48 -> $0.39
8/14/2015	Roth Capital	Reiterated Rating	Buy	$4.50
6/1/2015	Janney Montgomery Scott	Reiterated Rating	Buy -> Fair Value	$3.50 -> $1.94
5/10/2015	HC Wainwright	Reiterated Rating	Buy	$6.00 -> $4.00

(Data available from 9/26/2014 forward)

Earnings History for CTI BioPharma Corp. (NASDAQ:CTIC)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/3/2016
8/4/2016	Q2	($0.10)	($0.07)			View	N/A
5/10/2016	Q1	($0.04)	$0.01			View	N/A
2/16/2016	Q4	($0.18)	($0.13)			View	N/A
11/5/2015	Q315	($0.12)	($0.19)	$18.89 million	$1.00 million	View	Listen
8/6/2015	Q215	($0.10)	($0.19)	$12.77 million	$1.10 million	View	Listen
5/6/2015	Q115	($0.14)	($0.16)	$9.84 million	$2.73 million	View	Listen
3/12/2015	Q414	($0.18)	($0.27)	$2.48 million	$17.80 million	View	Listen
10/29/2014	Q3	$0.03	$0.03			View	Listen
8/4/2014	Q2	($0.12)	($0.19)			View	Listen
4/29/2014	Q114	($0.17)	($0.20)	$1.10 million	$1.40 million	View	N/A
3/4/2014	Q4	($0.16)	$0.08	$1.26 million	$32.90 million	View	Listen
2/28/2013	Q4 2012	($0.20)	($0.20)	$1.00 million		View	Listen
11/1/2012	Q312		($0.38)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for CTI BioPharma Corp. (NASDAQ:CTIC)

Current Year EPS Consensus Estimate: $-0.190 EPS
Next Year EPS Consensus Estimate: $-0.230 EPS

Dividend History for CTI BioPharma Corp. (NASDAQ:CTIC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for CTI BioPharma Corp. (NASDAQ:CTIC)

Insider Ownership Percentage: 3.01%
Institutional Ownership Percentage: 28.96%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
6/24/2016	James A Bianco	CEO	Sell	10,000	$0.37	$3,700.00
5/27/2016	James A Bianco	CEO	Sell	10,000	$0.45	$4,500.00
4/29/2016	James A Bianco	CEO	Sell	10,000	$0.52	$5,200.00
3/28/2016	James A Bianco	CEO	Sell	10,000	$0.49	$4,900.00
3/21/2016	James A Bianco	CEO	Sell	318,169	$0.55	$174,992.95
3/4/2016	Matthew Plunkett	EVP	Sell	10,000	$0.59	$5,900.00
2/26/2016	Jack W Singer	EVP	Sell	15,000	$0.63	$9,450.00
2/26/2016	James A Bianco	CEO	Sell	10,000	$0.63	$6,300.00
2/16/2016	James A Bianco	CEO	Sell	100,000	$0.42	$42,000.00
2/4/2016	Matthew Plunkett	EVP	Sell	10,000	$1.15	$11,500.00
1/29/2016	Jack W. Singer	EVP	Sell	15,000	$1.18	$17,700.00
1/29/2016	James A Bianco	CEO	Sell	10,000	$1.20	$12,000.00
1/8/2016	Value Fund L P Biotechnology	Insider	Buy	1,001,327	$1.22	$1,221,618.94
1/4/2016	Matthew Plunkett	EVP	Sell	10,000	$1.21	$12,100.00
12/30/2015	James A. Bianco	CEO	Sell	110,000	$1.26	$138,600.00
12/28/2015	James A. Bianco	CEO	Sell	10,000	$1.29	$12,900.00
12/18/2015	Jack W. Singer	EVP	Sell	15,000	$1.18	$17,700.00
12/4/2015	Matthew Plunkett	EVP	Sell	10,000	$1.00	$10,000.00
11/27/2015	Jack W. Singer	EVP	Sell	15,000	$1.21	$18,150.00
11/27/2015	James A Bianco	CEO	Sell	10,000	$1.23	$12,300.00
11/19/2015	Louis A. Bianco	EVP	Sell	15,000	$1.13	$16,950.00
10/30/2015	James A Bianco	CEO	Sell	260,000	$1.35	$351,000.00
10/29/2015	Louis A. Bianco	EVP	Sell	10,000	$1.41	$14,100.00
10/23/2015	Jack W. Singer	EVP	Sell	15,000	$1.62	$24,300.00
10/22/2015	Louis A Bianco	EVP	Sell	10,000	$1.58	$15,800.00
10/5/2015	Matthew Plunkett	EVP	Sell	10,000	$1.52	$15,200.00
9/30/2015	Jack W. Singer	EVP	Sell	100,000	$1.42	$142,000.00
9/30/2015	James A. Bianco	CEO	Sell	600,000	$1.43	$858,000.00
9/30/2015	Richard L. Love	Director	Sell	13,660	$1.45	$19,807.00
9/29/2015	Louis A. Bianco	EVP	Sell	170,000	$1.41	$239,700.00
9/25/2015	Jack W. Singer	EVP	Sell	15,000	$1.64	$24,600.00
9/24/2015	Matthew Plunkett	EVP	Sell	75,869	$1.57	$119,114.33
9/4/2015	Matthew Plunkett	EVP	Sell	10,000	$1.54	$15,400.00
8/28/2015	Jack W. Singer	EVP	Sell	15,000	$1.58	$23,700.00
7/24/2015	Jack W Singer	EVP	Sell	15,000	$1.91	$28,650.00
7/23/2015	Louis A Bianco	EVP	Sell	10,000	$1.91	$19,100.00
7/6/2015	Matthew Plunkett	EVP	Sell	10,000	$1.95	$19,500.00
6/26/2015	Jack W Singer	EVP	Sell	15,000	$2.07	$31,050.00
6/25/2015	Louis A Bianco	EVP	Sell	10,000	$2.18	$21,800.00
6/4/2015	Matthew Plunkett	EVP	Sell	10,000	$2.06	$20,600.00
5/22/2015	Jack W Singer	EVP	Sell	15,000	$1.74	$26,100.00
5/21/2015	Louis A Bianco	EVP	Sell	10,000	$1.80	$18,000.00
5/4/2015	Matthew Plunkett	EVP	Sell	10,000	$1.86	$18,600.00
4/24/2015	Jack W Singer	EVP	Sell	15,000	$1.96	$29,400.00
4/23/2015	Louis A Bianco	EVP	Sell	10,000	$1.93	$19,300.00
4/6/2015	Matthew Plunkett	EVP	Sell	16,569	$1.88	$31,149.72
3/23/2015	James A Bianco	CEO	Sell	175,199	$1.95	$341,638.05
3/23/2015	Matthew Plunkett	EVP	Sell	59,130	$1.96	$115,894.80
3/20/2015	Louis A Bianco	EVP	Sell	63,000	$1.94	$122,220.00
2/27/2015	Jack W Singer	EVP	Sell	15,000	$2.35	$35,250.00
2/5/2015	Louis A Bianco	EVP	Sell	10,000	$2.22	$22,200.00
2/4/2015	Matthew Plunkett	EVP	Sell	12,000	$2.22	$26,640.00
1/8/2015	Louis A Bianco	EVP	Sell	10,000	$2.32	$23,200.00
1/5/2015	Matthew Plunkett	EVP	Sell	12,000	$2.36	$28,320.00
12/19/2014	James A Bianco	CEO	Sell	40,000	$2.44	$97,600.00
12/4/2014	Louis A Bianco	EVP	Sell	10,000	$2.25	$22,500.00
11/6/2014	Louis A Bianco	EVP	Sell	10,000	$2.37	$23,700.00
10/6/2014	Matthew Plunkett	EVP	Sell	12,000	$2.39	$28,680.00
9/23/2014	Matthew Plunkett	EVP	Sell	103,635	$2.56	$265,305.60
9/22/2014	James A Bianco	CEO	Sell	307,068	$2.53	$776,882.04
9/22/2014	Matthew Plunkett	EVP	Sell	51,817	$2.58	$133,687.86
9/19/2014	Louis A Bianco	EVP	Sell	145,000	$2.59	$375,550.00
9/4/2014	Matthew Plunkett	EVP	Sell	27,301	$2.48	$67,706.48
8/15/2014	James A Bianco	CEO	Sell	40,000	$2.54	$101,600.00
8/4/2014	Matthew Plunkett	EVP	Sell	12,000	$2.48	$29,760.00
7/10/2014	Louis A Bianco	EVP	Sell	10,000	$2.73	$27,300.00
7/7/2014	Matthew Plunkett	EVP	Sell	12,000	$2.89	$34,680.00
6/27/2014	James A Bianco	CEO	Sell	50,000	$2.84	$142,000.00
6/5/2014	Louis A Bianco	EVP	Sell	10,000	$2.97	$29,700.00
5/1/2014	Louis Bianco	EVP	Sell	10,000	$2.91	$29,100.00
3/28/2014	Vartan Gregorian	Director	Sell	82,000	$3.41	$279,620.00
3/25/2014	Phillip Phd Nudelman	Director	Sell	100,000	$3.56	$356,000.00
3/24/2014	Jack Singer	EVP	Sell	60,000	$3.47	$208,200.00
3/21/2014	James Bianco	CEO	Sell	395,000	$3.83	$1,512,850.00
3/21/2014	Matthew Plunkett	EVP	Sell	170,000	$3.73	$634,100.00
3/7/2014	Fred Telling	Director	Sell	72,095	$3.75	$270,356.25
9/23/2013	James A Bianco	CEO	Sell	130,551	$1.50	$195,826.50
8/30/2013	James A Bianco	CEO	Sell	25,925	$1.08	$27,999.00
8/9/2013	James A Bianco	CEO	Sell	40,000	$1.07	$42,800.00
8/7/2013	Mary Oneil Mundinger	Director	Sell	125,000	$1.06	$132,500.00
8/6/2013	Phillip M Phd Nudelman	Director	Sell	50,000	$1.09	$54,500.00
7/26/2013	James A Bianco	CEO	Sell	25,688	$1.09	$27,999.92
6/28/2013	James A Bianco	CEO	Sell	26,053	$1.08	$28,137.24
6/5/2013	Jack W Singer	EVP	Sell	10,000	$1.26	$12,600.00
5/31/2013	James A Bianco	CEO	Sell	28,000	$1.22	$34,160.00
5/31/2013	Louis A Bianco	EVP	Sell	33,712	$1.24	$41,802.88
5/30/2013	Fred Telling	Director	Sell	64,798	$1.24	$80,349.52
5/24/2013	Richard L Love	Director	Sell	23,000	$1.21	$27,830.00
5/10/2013	James A Bianco	CEO	Sell	25,000	$1.16	$29,000.00
5/9/2013	Louis A Bianco	EVP	Sell	50,000	$1.15	$57,500.00
3/11/2013	Jack W Singer	EVP	Sell	13,000	$1.28	$16,640.00
8/10/2012	James A Bianco	CEO	Sell	10,000	$0.42	$4,200.00

(Data available from 1/1/2013 forward)

Latest Headlines for CTI BioPharma Corp. (NASDAQ:CTIC)

Date	Headline
	Keen Investors Find News on CTI BioPharma Corp. (NASDAQ:CTIC) - Duncan Research (NASDAQ:CTIC) www.duncanindependent.com - September 24 at 4:15 PM
	Under the Microscope, Zeroing in at CTI BioPharma Corp. (NASDAQ:CTIC) - Duncan Research (NASDAQ:CTIC) www.duncanindependent.com - September 23 at 9:33 AM
	CTI BioPharma Granted 180 Day Extension By NASDAQ To Regain ... - PR Newswire (press release) (NASDAQ:CTIC) www.prnewswire.com - September 23 at 9:33 AM
	News review of 2 biotech stocks: CTI BioPharma Corp. (NASDAQ:CTIC), PTC Therapeutics, Inc. (NASDAQ:PTCT) - The Voice Registrar (NASDAQ:CTIC) voiceregistrar.com - September 23 at 9:33 AM
	CTI BioPharma Granted 180 Day Extension By NASDAQ To Regain Compliance With Minimum Bid Price Rule (NASDAQ:CTIC) finance.yahoo.com - September 22 at 10:03 AM
	Penny Stock Investors Keen on Shares of CTI BioPharma Corp. (NASDAQ:CTIC) - Duncan Research (NASDAQ:CTIC) www.duncanindependent.com - September 21 at 5:01 PM
	CTI BioPharma Corp. (NASDAQ:CTIC) Near Term Price Target Update on The Stock - Frisco Fastball (NASDAQ:CTIC) friscofastball.com - September 21 at 8:42 AM
	CTI BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits (NASDAQ:CTIC) biz.yahoo.com - September 20 at 8:06 AM
	Mean Consensus Price Target for CTI BioPharma Corp. (NASDAQ:CTIC) is Set at 0.75 - Frisco Fastball (NASDAQ:CTIC) friscofastball.com - September 18 at 4:21 PM
	CTI BioPharma Corp. (NASDAQ:CTIC): A look at the Stock Performance Today and Where it Could be Headed - Frisco Fastball (NASDAQ:CTIC) friscofastball.com - September 18 at 4:21 PM
	CTI BioPharma Corp. (NASDAQ:CTIC): Stock Update & Outlook on Consensus Direction - Frisco Fastball (NASDAQ:CTIC) friscofastball.com - September 17 at 4:22 PM
	Keen Investors Seek Information on CTI BioPharma Corp. (NASDAQ:CTIC) - Duncan Research (NASDAQ:CTIC) www.duncanindependent.com - September 16 at 4:21 PM
	Stock Update, a Closer Look at CTI BioPharma Corp. (NASDAQ:CTIC) - Duncan Research (NASDAQ:CTIC) www.duncanindependent.com - September 16 at 8:05 AM
	Keen Investors Narrowing Their Focus on CTI BioPharma Corp. (NASDAQ:CTIC) - Duncan Research (NASDAQ:CTIC) www.duncanindependent.com - September 15 at 9:25 AM
	Investor Scope: Checking in on Shares of CTI BioPharma Corp. (NASDAQ:CTIC) - Post News (NASDAQ:CTIC) www.kentuckypostnews.com - September 14 at 8:05 AM
	Honing in on CTI BioPharma Corp. (NASDAQ:CTIC) Shares, Analysts Take Stock - Frisco Fastball (NASDAQ:CTIC) friscofastball.com - September 13 at 9:20 AM
	CTI BioPharma Corp. (NASDAQ:CTIC) are Projected to Reach 0.75, According to Analysts - Frisco Fastball (NASDAQ:CTIC) friscofastball.com - September 11 at 8:59 AM
	CTI BioPharma Corp. (NASDAQ:CTIC) Shares Handed One Year Price Objective - Frisco Fastball (NASDAQ:CTIC) friscofastball.com - September 11 at 8:59 AM
	Market Review: Watching Session Activity of CTI BioPharma Corp. (NASDAQ:CTIC) Shares - Post News (NASDAQ:CTIC) www.kentuckypostnews.com - September 9 at 4:20 PM
	CTI BioPharma Corp. (NASDAQ:CTIC) Shares Are Moving, But Where to go From Here? - Frisco Fastball (NASDAQ:CTIC) friscofastball.com - September 9 at 9:18 AM
	Trading Update: Following Activity of CTI BioPharma Corp. (NASDAQ:CTIC) Shares During the Current Session - Post News (NASDAQ:CTIC) www.kentuckypostnews.com - September 8 at 8:13 AM
	CTI BioPharma Corp. (NASDAQ:CTIC): Can It Hit The Consensus of $0.75? - Frisco Fastball (NASDAQ:CTIC) friscofastball.com - September 8 at 8:13 AM
	Shares Gapping Higher Pre-Bell: CTI BioPharma Corp. (NASDAQ:CTIC) - Post News (NASDAQ:CTIC) www.kentuckypostnews.com - September 1 at 10:19 AM
	Intraday Active Biotech Stocks News: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), CTI BioPharma Corp. (NASDAQ ... - The Voice Registrar (NASDAQ:CTIC) voiceregistrar.com - September 1 at 10:19 AM
	Piper Remains Neutral on CTI BioPharma (CTIC) Update Top-Line PERSIST-2 Data (NASDAQ:CTIC) www.streetinsider.com - August 31 at 4:25 PM
	CTI BioPharma Corp.'s (CTIC): Stock in the Traders Limelight - Hot Stocks Point (NASDAQ:CTIC) www.hotstockspoint.com - August 31 at 9:15 AM
	Shares Gapping Higher Pre-Market: CTI BioPharma Corp. (NASDAQ:CTIC) - Post News (NASDAQ:CTIC) www.kentuckypostnews.com - August 30 at 6:40 AM
	CTI BioPharma (CTIC) Announces Pacritinib Phase 3 Met One co-Primary Endpoint; TSS Reduction Endpoint Missed (NASDAQ:CTIC) www.streetinsider.com - August 29 at 4:39 PM
	CTI BioPharma Meets One Of Two Endpoints In Phase 3 Trial (NASDAQ:CTIC) feeds.benzinga.com - August 29 at 2:01 PM
	CTI: Pacritinib End Trial For Advanced Myelofibrosis Met One Of Co-primary Goals (NASDAQ:CTIC) www.rttnews.com - August 29 at 9:10 AM
	CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis (NASDAQ:CTIC) finance.yahoo.com - August 29 at 9:10 AM
	CTI BioPharma Corp (NASDAQ:CTIC) Analyst Opinion - The Independent Republic (NASDAQ:CTIC) theindependentrepublic.com - August 24 at 4:26 PM
	Time To Put On The Watch List? - CTI BioPharma Corp. (NASDAQ:CTIC), Spark Therapeutics, Inc. (NASDAQ:ONCE) - The Voice Registrar (NASDAQ:CTIC) voiceregistrar.com - August 18 at 9:41 PM
	CTI BIOPHARMA CORP Financials (NASDAQ:CTIC) finance.yahoo.com - August 13 at 4:27 PM
	BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:CTIC) www.publicnow.com - August 11 at 9:41 AM
	CTI BioPharma Corp. (CTIC) Jumps 7.24% on August 03 \| Equities ... - Equities.com (NASDAQ:CTIC) www.equities.com - August 5 at 10:40 AM
	EARNINGS SUMMARY: Details of CTI BioPharma Corp. Q2 Earnings Report (NASDAQ:CTIC) www.rttnews.com - August 4 at 10:10 PM
	CTI BioPharma reports 2Q loss (NASDAQ:CTIC) sg.finance.yahoo.com - August 4 at 10:09 PM
	CTI BioPharma Reports Second Quarter 2016 Financial Results (NASDAQ:CTIC) finance.yahoo.com - August 4 at 4:41 PM
	The Insider Activity Don't Lie: CTI BioPharma Corp. (NASDAQ:CTIC ... - Review Fortune (NASDAQ:CTIC) reviewfortune.com - August 2 at 4:35 PM
	Analysts Ranking Activities: Sophiris Bio, Inc. (NASDAQ:SPHS) , CTI BioPharma Corp. (NASDAQ:CTIC) - Street Updates (NASDAQ:CTIC) www.streetupdates.com - August 2 at 9:16 AM
	Keep an eye on Analyst Actions: CTI BioPharma Corp. (NASDAQ:CTIC) , Novo Nordisk A/S (NYSE:NVO) - Street Updates (NASDAQ:CTIC) www.streetupdates.com - July 27 at 10:10 PM
	CTI BioPharma Corp. (CTIC) Drops 9.12% on July 26 \| Equities.com - Equities.com (NASDAQ:CTIC) www.equities.com - July 27 at 10:10 PM
	Shares Stumbling of Late: CTI BioPharma Corp. (NASDAQ:CTIC) - TGP (NASDAQ:CTIC) telanaganapress.com - July 23 at 8:08 AM
	Street Analyst EPS Growth Watch in Review CTI BioPharma Corp. (NASDAQ:CTIC) - TGP (NASDAQ:CTIC) telanaganapress.com - July 22 at 3:52 PM
	Concentrating on Shares of CTI BioPharma Corp. (NASDAQ:CTIC) - Press Telegraph (NASDAQ:CTIC) presstelegraph.com - July 21 at 4:36 PM
	Market Minute - Focus on CTI BioPharma Corp. (NASDAQ:CTIC) Stock - TGP (NASDAQ:CTIC) telanaganapress.com - July 21 at 4:36 PM
	ETF’s with exposure to CTI BioPharma Corp. : July 20, 2016 (NASDAQ:CTIC) www.capitalcube.com - July 20 at 12:18 PM
	Session Focus - Highlighting Shares of: CTI BioPharma Corp. (NASDAQ:CTIC) - TGP (NASDAQ:CTIC) telanaganapress.com - July 19 at 4:32 PM
	UPDATE 1-Brainstorm's cell therapy succeeds in ALS mid-stage study (NASDAQ:CTIC) feeds.reuters.com - July 18 at 9:49 AM